1st Edition

Pharmaceutical Biocatalysis Important Enzymes, Novel Targets, and Therapies

Edited By Peter Grunwald Copyright 2020
    478 Pages 22 Color & 77 B/W Illustrations
    by Jenny Stanford Publishing

    478 Pages 22 Color & 77 B/W Illustrations
    by Jenny Stanford Publishing

    This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.

    Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes

    Monika Sharma, Tanya Bajaj, and Rohit Sharma


    Moritz Helmstädter, Manfred Schubert-Zsilavecz

    Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency

    Mariarita Bertoldi and Giada Rossignoli

    Advancing Phospholipase D Enzymes as Diverse Drug Targets

    Hortensia Gomes Leal and Kimberly A. Stieglitz

    IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives

    Angelo Paci et al.

    Enzymes for Prodrug-Activation in Cancer Treatment and Gene Therapies

    Peter Grunwald

    Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer

    Mohammad Hojjat-Farsangi and Reza Khamisipour

    β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors

    Ulrike Holzgrabe and Jens Schmitz

    Non-Vitamin K Oral Anticoagulants (NOACs): New Options

    Susanne Alban

    Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease

    J. K. Liao

    Lysosomal Storage Disorders and Enzyme Replacement Therapy

    Peter Grunwald


    Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.